PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2017 Edition is a new market research publication announced by Reportstack. This report provides information on Where’s your place in the CMO hierarchy?
Find out in the CMO industry’s authoritative analysis of manufacturing of NDA approvals. This CMO scorecard was compiled through hundreds of professional hours of research and analysis, and is presented in a 40-page report with over 30 graphs and tables. Only CMO Scorecard enables the CMO industry to benchmark its performance over time, and CMOs to benchmark their performance against the industry.
Our research team crunched the numbers on 2016 drug approvals authorized by FDA’s CDER, CBER, Fast Track and Breakthrough drugs, and selected EMA approved drugs. For the first time, we are including information on the location of outsourced dose manufacturing facilities.
Complete report available @ PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2017 Edition
Reasons to buy
This report is required reading for -
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
No comments:
Post a Comment